NCT03988842View on ClinicalTrials.gov

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

PHASE4TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 25, 2019

Primary Completion Date

April 5, 2020

Study Completion Date

April 5, 2020

Conditions
Pulmonary Embolism With Acute Cor PulmonalePulmonary EmbolismPulmonary Embolism With Pulmonary InfarctionPulmonary Embolism Subacute MassiveRight Ventricular DysfunctionRight Ventricular Failure
Interventions
DRUG

Alteplase

Lyophilized powder for reconstitution in 50mg vials

DRUG

Unfractionated heparin

Heparin sodium in 0.45% sodium chloride injection for intravenous use

DRUG

Placebo

Saline solution reconstituted to mimic Alteplase 50mg vial

DRUG

Apixaban

Apixaban tablet

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Victor Tapson, MD

OTHER